Table 3.

Significant independent predictors of the HRV parameters in T1DM population: multivariate regression analyses.

	B	β	p	F	adj. R 2	p
ln SDNN				12.719	0.366	< 0.001
HbA1c (%)	-0.142	0.395	< 0.001
BMI (kg/m2)	-0.027	-0.259	0.016
Age (years)	-0.011	-0.257	0.019
Disease duration (years)		-0.17	0.889
Office blood pressure, systolic (mmHg)		-0.19	0.862
Smoking (n/p/c)		-0.180	0.083
eGFR (ml/min/1.73 m 2 )		0.119	0.308
Use of ACE inhibitors/ARBs (y/n)		0.113	0.365
Use of beta receptor antagonists (y/n)		0.085	0.472
ln rMSSD				11.436	0.255	< 0.001
HbA1c (%)	-0.167	-0.405	< 0.001
eGFR (ml/min/1.73 m2)	0.008	0.280	0.015
Age (years)		-0.154	0.222
BMI (kg/m 2 )		-0.215	0.060
Disease duration (years)		-0.097	0.409
Office blood pressure, systolic (mmHg)		-0.065	0.563
Use of ACE inhibitors/ARBs (y/n)		-0.081	0.498
ln VLF				14.108	0.172	< 0.001
HbA1c (%)	-0.321	-0.431	< 0.001
Age (years)		-0.231	0.051
BMI (kg/m 2 )		-0.185	0.112
Office blood pressure, systolic (mmHg)		-0.216	0.061
eGFR (ml/min/1.73 m 2 )		0.170	0.145
Use of ACE inhibitors/ARBs (y/n)		-0.106	0.385
ln LF				13.207	0.375	< 0.001
HbA1c (%)	-0.311	-0.336	0.002
Age (years)	-0.034	-0.325	0.003
BMI (kg/m2)	-0.072	-0.270	0.012
Gender (male/female)		-0.185	0.071
Disease duration (years)		-0.033	0.781
Office blood pressure, systolic (mmHg)		-0.057	0.592
Smoking (n/p/c)		-0.113	0.278
eGFR (ml/min/1.73 m 2 )		0.012	0.917
Use of ACE inhibitors/ARBs (y/n)		0.010	0.938
Use of beta receptor antagonists (y/n)		0.011	0.927
ln HF				11.975	0.265	< 0.001
Age (years)	-0.045	-0.353	0.003
HbA1c (%)	-0.363	-0.326	0.006
BMI (kg/m 2 )		-0.173	0.125
Disease duration (years)		-0.111	0.388
Office blood pressure, systolic (mmHg)		-0.088	0.434
Smoking (n/p/c)		-0.102	0.364
eGFR (ml/min/1.73 m 2 )		0.118	0.337
Use of ACE inhibitors/ARBs (y/n)		-0.036	0.765
ln LF/HF ratio				5.787	0.067	0.019
Disease duration (years)	0.020	0.284	0.019
Gender (male/female)		-0.213	0.072
ln Total Power				12.346	0.271	< 0.001
HbA1c (%)	-0.295	-0.357	0.002
Age (years)	-0.031	-0.329	0.005
BMI (kg/m 2 )		-0.196	0.079
Disease duration (years)		0.004	0.978
Office blood pressure, systolic (mmHg)		-0.133	0.232
Smoking (n/p/c)		-0.122	0.271
eGFR (ml/min/1.73 m 2 )		0.081	0.507
Use of ACE inhibitors/ARBs (y/n)		-0.046	0.703
Use of beta receptor antagonists (y/n)		0.023	0.852
ln SD1				8.413	0.267	< 0.001
HbA1c (%)	-0.148	-0.323	0.006
Age (years)	-0.013	-0.246	0.035
BMI (kg/m2)	-0.031	-0.233	0.042
Disease duration (years)		-0.036	0.781
Office blood pressure, systolic (mmHg)		-0.022	0.851
eGFR (ml/min/1.73 m 2 )		0.150	0.231
Use of ACE inhibitors/ARBs (y/n)		0.042	0.752
ln SD2				10.016	0.372	< 0.001
HbA1c (%)	-0.111	-0.296	0.007
Age (years)	-0.011	-0.269	0.014
BMI (kg/m2)	-0.033	-0.302	0.005
Smoking	-0.128	-0.219	0.038
Disease duration (years)		0.008	0.949
Office blood pressure, systolic (mmHg)		0.016	0.885
eGFR (ml/min/1.73 m 2 )		0.100	0.388
Use of ACE inhibitors/ARBs (y/n)		0.062	0.618
Use of beta receptor antagonists (y/n)		0.054	0.650

Unstandardized (B) and standardized (β) regression coefficients. Statistically significant p-values (p < 0.05) are formatted in bold.